{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T08:05:15Z","timestamp":1776413115313,"version":"3.51.2"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s13300-025-01790-z","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T03:48:33Z","timestamp":1763437713000},"page":"93-111","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Once-Weekly Semaglutide in Japanese Patients with Type 2 Diabetes: A Retrospective Observational Multicenter Study (ORIGAMI Study)"],"prefix":"10.1007","volume":"17","author":[{"given":"Yoko","family":"Iwata","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fukumi","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayako","family":"Fuchigami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Genki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuhito","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takamasa","family":"Ichijyo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadamasa","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Hirose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9282-918X","authenticated-orcid":false,"given":"Hiroshi","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1790_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;157:107843.","journal-title":"Diabetes Res Clin Pract"},{"key":"1790_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.2337\/dc15-1536","volume":"39","author":"A Nanditha","year":"2016","unstructured":"Nanditha A, Ma RCW, Ramachandran A, et al. Diabetes in Asia and the Pacific: implications for the global epidemic. Diabetes Care. 2016;39:472\u201385.","journal-title":"Diabetes Care"},{"key":"1790_CR3","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.2337\/dc12-1235","volume":"36","author":"K Kodama","year":"2013","unstructured":"Kodama K, Tojjar D, Yamada S, et al. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care. 2013;36:1789\u201396.","journal-title":"Diabetes Care"},{"key":"1790_CR4","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1111\/dom.14451","volume":"23","author":"A Tsapas","year":"2021","unstructured":"Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021;23:2116\u201324.","journal-title":"Diabetes Obes Metab"},{"key":"1790_CR5","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"1790_CR6","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","volume":"138","author":"JFE Mann","year":"2018","unstructured":"Mann JFE, Fonseca V, Mosenzon O, et al. Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease. Circulation. 2018;138:2908\u201318.","journal-title":"Circulation"},{"key":"1790_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121\u201330.","journal-title":"Lancet"},{"key":"1790_CR8","doi-asserted-by":"publisher","first-page":"S158","DOI":"10.2337\/dc24-S009","volume":"47","author":"American Diabetes Association Professional Practice Committee","year":"2024","unstructured":"American Diabetes Association Professional Practice Committee. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2024. Diabetes Care. 2024;47:S158\u201378.","journal-title":"Diabetes Care"},{"key":"1790_CR9","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/dom.13218","volume":"20","author":"K Kaku","year":"2018","unstructured":"Kaku K, Yamada Y, Watada H, et al. Safety and efficacy of once-weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: a randomized trial. Diabetes Obes Metab. 2018;20:1202\u201312.","journal-title":"Diabetes Obes Metab"},{"key":"1790_CR10","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/dom.13082","volume":"20","author":"Y Seino","year":"2018","unstructured":"Seino Y, Terauchi Y, Osonoi T, et al. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes. Diabetes Obes Metab. 2018;20:378\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"1790_CR11","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR12","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258\u201366.","journal-title":"Diabetes Care"},{"key":"1790_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig A-M, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46:100\u20139.","journal-title":"Diabetes Metab"},{"key":"1790_CR14","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1111\/dom.14453","volume":"23","author":"VR Aroda","year":"2021","unstructured":"Aroda VR, Faurby M, Lophaven S, et al. Insights into the early use of oral semaglutide in routine clinical practice: The IGNITE study. Diabetes Obes Metab. 2021;23:2177\u201382.","journal-title":"Diabetes Obes Metab"},{"key":"1790_CR15","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1007\/s13300-022-01313-0","volume":"13","author":"H Yamada","year":"2022","unstructured":"Yamada H, Yoshida M, Suzuki D, et al. Effectiveness and safety of once-weekly semaglutide in Japanese patients with type 2 diabetes in treatment intensification: a retrospective observational single-center study. Diabetes Ther. 2022;13:1779\u201388.","journal-title":"Diabetes Ther"},{"key":"1790_CR16","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/ijo.2009.29","volume":"33","author":"T Shimazu","year":"2009","unstructured":"Shimazu T, Kuriyama S, Ohmori-Matsuda K, et al. Increase in body mass index category since age 20 years and all-cause mortality: a prospective cohort study (the Ohsaki Study). Int J Obes (Lond). 2009;33:490\u20136.","journal-title":"Int J Obes (Lond)"},{"key":"1790_CR17","unstructured":"Japan Society of Hepatology. Nara Declaration 2023. 2024.https:\/\/www.jsh.or.jp\/lib\/files\/english\/nara_declaration2023.pdf. Accessed"},{"key":"1790_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/jgh3.13110","volume":"8","author":"T Miwa","year":"2024","unstructured":"Miwa T, Tajirika S, Imamura N, et al. Usefulness of health checkup-based indices in identifying metabolic dysfunction-associated steatotic liver disease. JGH Open. 2024;8:e13110.","journal-title":"JGH Open"},{"key":"1790_CR19","doi-asserted-by":"publisher","first-page":"186","DOI":"10.2957\/kanzo.65.186","volume":"65","author":"M Kawanaka","year":"2024","unstructured":"Kawanaka M, Fujii H, Iwaki M, et al. Importance of ALT levels of >30 in patients with MASLD: Nara declaration 2023. Kanzo. 2024;65:186\u201391.","journal-title":"Kanzo"},{"key":"1790_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1177\/1536867X211045512","volume":"21","author":"S Nash","year":"2021","unstructured":"Nash S, Morgan KE, Frost C, et al. Power and sample-size calculations for trials that compare slopes over time: introducing the slopepower command. Stata J. 2021;21:575\u2013601.","journal-title":"Stata J"},{"key":"1790_CR21","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.2147\/DMSO.S483065","volume":"17","author":"Z Ruan","year":"2024","unstructured":"Ruan Z, Chen X, Song M, et al. Real-world utilization and effectiveness of glucagon-like peptide-1 receptor agonists dosed weekly and daily in patients with type 2 diabetes mellitus: results from retrospective electronic medical records in China. Diabetes Metab Syndr Obes. 2024;17:3657\u201366.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"1790_CR22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1007\/s40271-017-0225-0","volume":"10","author":"A Ryd\u00e9n","year":"2017","unstructured":"Ryd\u00e9n A, Chen S, Flood E, et al. Discrete choice experiment attribute selection using a multinational interview study: treatment features important to patients with type 2 diabetes mellitus. Patient. 2017;10:475\u201387.","journal-title":"Patient"},{"key":"1790_CR23","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1136\/bmj.321.7258.405","volume":"321","author":"IM Stratton","year":"2000","unstructured":"Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405\u201312.","journal-title":"BMJ"},{"key":"1790_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR25","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR26","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"1790_CR27","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR28","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","volume":"7","author":"I Lingvay","year":"2019","unstructured":"Lingvay I, Catarig A-M, Frias JP, et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes Endocrinol. 2019;7:834\u201344.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR29","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/jdi.13773","volume":"13","author":"D Yabe","year":"2022","unstructured":"Yabe D, Yamada Y, Kaku K, et al. Efficacy and safety of once-weekly semaglutide in Japanese individuals with type 2 diabetes by baseline age and body mass index. J Diabetes Investig. 2022;13:1161\u201374.","journal-title":"J Diabetes Investig"},{"key":"1790_CR30","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","volume":"9","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, et al. Efficacy and safety of once-weekly semaglutide 2\u00b70 mg versus 1\u00b70 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. Lancet Diabetes Endocrinol. 2021;9:563\u201374.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2019;7:356\u201367.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1790_CR32","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/biomedicines12051001","volume":"12","author":"H Katsuyama","year":"2024","unstructured":"Katsuyama H, Hakoshima M, Kaji E, et al. Effects of once-weekly semaglutide on cardiovascular risk factors and metabolic dysfunction-associated steatotic liver disease in Japanese patients with type 2 diabetes: a retrospective longitudinal study based on real-world data. Biomedicines. 2024;12:1001.","journal-title":"Biomedicines"},{"key":"1790_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s13300-022-01218-y","volume":"13","author":"C Di Loreto","year":"2022","unstructured":"Di Loreto C, Minarelli V, Nasini G, et al. Effectiveness in real world of once weekly semaglutide in people with type 2 diabetes: glucagon-like peptide receptor agonist na\u00efve or switchers from other glucagon-like peptide receptor agonists: results from a retrospective observational study in Umbria. Diabetes Ther. 2022;13:551\u201367.","journal-title":"Diabetes Ther"},{"key":"1790_CR34","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s13300-021-01015-z","volume":"12","author":"DM Williams","year":"2021","unstructured":"Williams DM, Ruslan AM, Khan R, et al. Real-world clinical experience of semaglutide in secondary care diabetes: a retrospective observational study. Diabetes Ther. 2021;12:801\u201311.","journal-title":"Diabetes Ther"},{"key":"1790_CR35","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, et al. The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"key":"1790_CR36","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1790_CR37","doi-asserted-by":"publisher","unstructured":"Nevola R, Epifani R, Imbriani S, et al. GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives. Int J Mol Sci. 2023;24(2):1703. https:\/\/doi.org\/10.3390\/ijms24021703.","DOI":"10.3390\/ijms24021703"},{"key":"1790_CR38","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.21006","volume":"43","author":"X Ding","year":"2006","unstructured":"Ding X, Saxena NK, Lin S, et al. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice. Hepatology. 2006;43:173\u201381.","journal-title":"Hepatology"},{"key":"1790_CR39","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.diabres.2015.12.003","volume":"113","author":"S Savvidou","year":"2016","unstructured":"Savvidou S, Karatzidou K, Tsakiri K, et al. Circulating adiponectin levels in type 2 diabetes mellitus patients with or without non-alcoholic fatty liver disease: results of a small, open-label, randomized controlled intervention trial in a subgroup receiving short-term exenatide. Diabetes Res Clin Pract. 2016;113:125\u201334.","journal-title":"Diabetes Res Clin Pract"},{"key":"1790_CR40","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1038\/mt.2008.198","volume":"16","author":"SL Samson","year":"2008","unstructured":"Samson SL, Gonzalez EV, Yechoor V, et al. Gene therapy for diabetes: metabolic effects of helper-dependent adenoviral exendin 4 expression in a diet-induced obesity mouse model. Mol Ther. 2008;16:1805\u201312.","journal-title":"Mol Ther"},{"key":"1790_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/apt.15316","volume":"50","author":"P Newsome","year":"2019","unstructured":"Newsome P, Francque S, Harrison S, et al. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and\/or obesity. Aliment Pharmacol Ther. 2019;50:193\u2013203.","journal-title":"Aliment Pharmacol Ther"},{"key":"1790_CR42","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0377","volume":"183","author":"DJ Wake","year":"2020","unstructured":"Wake DJ, Gibb FW, Kar P, et al. Endocrinology in the time of COVID-19: remodelling diabetes services and emerging innovation. Eur J Endocrinol. 2020;183:G67\u201377.","journal-title":"Eur J Endocrinol"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01790-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-025-01790-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-025-01790-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T07:17:40Z","timestamp":1769498260000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-025-01790-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1007\/s13300-025-01790-z","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoko Iwata, Manabu Saito, Ayako Fuchigami, Genki Sato, Atsuhito Saiki, Takamasa Ichijyo, Nobuyuki Sato, Tadamasa Ohashi, and Hiroshi Uchino declare that they have no competing interests. Takahisa Hirose received research funds from Nippon Boehringer Ingelheim Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Sumitomo Pharma Co., Ltd.; and lecture fees from Sanofi K.K., Eli Lilly Japan K.K., Novo Nordisk Pharma Ltd., MSD K.K., Abbott Medical Japan LLC, Mitsubishi Tanabe Pharma Corporation, Kowa Co., Ltd, and Sumitomo Pharma Co., Ltd. Atsuhito Saiki received research funds from Kowa Co., Ltd. Fukumi Yoshikawa received lecture fees from Sumitomo Pharma Co., Ltd. and Novo Nordisk Pharma Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki of 1964, as revised in 2013, and current legal regulations in Japan and was approved by the Ethics Committee at Toho University Graduate School of Medicine (approval #A23062_A22062). This study used non-identifiable data obtained by the training physicians, and therefore, based on the decision from our local Ethics Committee of Toho University Graduate School of Medicine (approval #A23062_#A22062), informed consent was not required. Patients had the opportunity to object to the use of their data for the retrospective scientific research; however, none of the patients objected. This study was registered in the University hospital Medical Information Network Clinical Trial Registry (UMIN000050499).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}